Essential Medicines Are More Available than Other Medicines around the Globe
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The World Health Organization (WHO) promotes the development of national Essential Medicines Lists (EMLs) in order to improve the availability and use of medicines considered essential within health care systems. However, despite over 3 decades of international efforts, studies show an inconsistent pattern in the availability of essential medicines. We evaluated and compared the availability of essential medicines, and medicines not included in national EMLs, at global and regional levels. METHODS: Medicine availability in the public and private sector were calculated based on data obtained from national and provincial facility-based surveys undertaken in 23 countries using the WHO/HAI methodology. The medicines were grouped according to their inclusion ('essential') or exclusion (termed 'non-essential') in each country's EML current at the time of the survey. Availability was calculated for originator brands, generics and any product type (originator brands or generics) and compared between the two groups. Results were aggregated by WHO regions, World Bank country income groups, a wealth inequality measure, and therapeutic groups. FINDINGS: Across all sectors and any product type, the median availability of essential medicines was suboptimal at 61·5% (IQR 20·6%-86·7%) but significantly higher than non-essential medicines at 27·3% (IQR 3·6%-70·0%). The median availability of essential medicines was 40·0% in the public sector and 78·1% in the private sector; compared to 6·6% and 57·1% for non-essential medicines respectively. A reverse trend between national income level categories and the availability of essential medicines was identified in the public sector. INTERPRETATION: EMLs have influenced the provision of medicines and have resulted in higher availability of essential medicines compared to non-essential medicines particularly in the public sector and in low and lower middle income countries. However, the availability of essential medicines, especially in the public sector does not ensure equitable access.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calamita, E., Schmid, M., Kunz, M., Ndebele-Murisa, M. R., Magadza, C. H. D., Nyambe, I., & Wehrli, B. (2019) · Figshare · doi:10.26181/6153922fe919c · Cited by 4,222
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928 · cited 3×
“The noticeable contribution of originator brand products to overall availability and extremely high prices of medicines compared to international reference prices [7] indicates the value of moving towards implementation of universal reimbursement systems that ensure equitable access to medicines for the entire society…”
Self-citationSodergren, E. H. (2007) · Cited by 257
Cameron, A., Roubos, I., Ewen, M., Mantel-Teeuwisse, A. K., Leufkens, H. G., & Laing, R. O. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.10.084327 · Cited by 187 · cited 3×
“[8] In our study, cardiovascular (antihypertensive and lipid modifying agents) and psychoanaleptic medicines were among the therapeutic groups for which the availability of essential medicines was far greater than non-essential medicines.”
Self-citationvan Mourik, M. S., Cameron, A., Ewen, M., & Laing, R. O. (2010) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-10-25 · Cited by 180 · cited 1×
“Several studies included assessments of the availability of medicines for acute versus chronic conditions [8], cardiovascular medicines in developing countries [9], anti-”
BackgroundSelf-citationCameron, A., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Laing, R. O. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.004 · Cited by 177 · cited 1×
“[33,34] The suboptimal availability of essential medicines in the public sector was observed in all WHO regions.”
Self-citationYang, H., Dib, H. H., Zhu, M., Qi, G., & Zhang, X. (2009) · Health Policy and Planning · doi:10.1093/heapol/czp056 · Cited by 87 · cited 1×
“[19] Conversely, a national study on the availability of pediatric essential medicines in Sri Lanka’s public sector [20] as well as provincial surveys on national essential medicines in China [21,22] all pointed to inadequate availability of the essential medicines studied.”
Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
Bertoldi, A. D., Helfer, A. P., Camargo, A. L., Tavares, N. U. L., & Kanavos, P. G. (2012) · Globalization and Health · doi:10.1186/1744-8603-8-6 · Cited by 80 · cited 1×
“Above 75% average availability of generic medicines was reported in a national survey of essential medicines in the private sector in Sri Lanka [15] and in the public sector and popular pharmacies in Brazil [16], as well as in provincial surveys on essential medicines in Ethiopia [17], primary health care centers’ ess…”
Chen, W., Tang, S., Sun, J., Ross-Degnan, D., & Wagner, A. K. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-211 · Cited by 79
Availability of essential medicines in Ethiopia: an efficiency‐equity trade‐off?
Carasso, B. S., Lagarde, M., Tesfaye, A., & Palmer, N. (2009) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2009.02383.x · Cited by 67 · cited 1×
“Above 75% average availability of generic medicines was reported in a national survey of essential medicines in the private sector in Sri Lanka [15] and in the public sector and popular pharmacies in Brazil [16], as well as in provincial surveys on essential medicines in Ethiopia [17], primary health care centers’ ess…”
Cited by
Items 101–126 of 126
Farid, N., Shah, M., Ali, A., & Jan, D. (2021) · Journal of Medical Sciences · doi:10.52764/jms.21.29.1.11 · Cited by 1
The AEIOU of essential diagnostics: align, expand, implement, oversee, and update
Oettingen, J. E. V., Ginsburg, O., Kishore, S. P., Pastakia, S. D., Schroeder, L. F., Milner, D. A., & Vedanthan, R. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30039-7 · Cited by 1
Bonfim, J. R. D. A. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2015.tde-17092015-084444 · Cited by 3
Three Approaches to Creating an Essential Diagnostics List
Guarner, J., Schroeder, L. F., & Amukele, T. K. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy167 · Cited by 1
A Case Study of the Registration of Essential Medicines in the East African CommunityPreprint
Green, A. K., Brhlíková, P., Ocan, M., & Pollock, A. M. (2021) · Research Square · doi:10.21203/rs.3.rs-885660/v1 · Cited by 1
Назаркіна, В. М. (2017) · News of pharmacy · doi:10.24959/nphj.17.2139
Impacting Global Health Delivery Through Advocacy: The Case of Losartan
Heller, D. J., & Kishore, S. P. (2018) · Global Heart · doi:10.1016/j.gheart.2018.11.001
Analysis of the expenses on pharmaceutical provision of newborns in Ukraine
Юрченко, Г. М. (2019) · Social pharmacy in health care · doi:10.24959/sphhcj.19.141
Schultz, R., & Lundmark, M. (2021) · Lund University Publications Student Papers (Lund University) · Cited by 1
Parra-Salas, L. E., & Edgar, L. (2021) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Evaluation of Prescribing Pattern of the Referring Cases at Sudan National Health Insurance Fund
Shagali Hana, E. H. (2019) · Journal of Quality in Health Care & Economics · doi:10.23880/jqhe-16000131
Tejesh, S., & Nagaveni, S. (2023) · Cureus · doi:10.7759/cureus.39341
ANTIBIOTICS IN INDONESIA: ACCESS, WATCH, AND RESERVE CLASSIFICATION
AMBARITA, D. S. A., Oktamianti, P., & Trisnadewi, I. G. A. (2024) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2024v16i3.50351
“The inclusion of antibiotic medicines list in the NEML and national formulary holds significant importance as it could substantially impact on their accessibility and utilization [21].”
BackgroundGuo, A., Pan, Z., & Tan, H. (2025) · Intelligent Pharmacy · doi:10.1016/j.ipha.2025.05.002
Lavtepatil, S., & Ghosh, S. (2022) · Figshare · doi:10.6084/m9.figshare.19766142
Additional file 1 of Biologic medicine inclusion in 138 national essential medicines lists
Kraus, R., Yeung, R. S. M., & Persaud, N. (2021) · Figshare · doi:10.6084/m9.figshare.16575458
Lavtepatil, S., & Ghosh, S. (2022) · Figshare · doi:10.6084/m9.figshare.19766139
Lavtepatil, S., & Ghosh, S. (2022) · Figshare · doi:10.6084/m9.figshare.19766145
Manyanga, V. P., Nyalali, N., Makoye, P. M., Sangeda, R. Z., Masota, N. E., Daniel, I. J., Tibalinda, P., & Kaale, E. A. (2025) · Cureus · doi:10.7759/cureus.100044
“Access to essential medicines is a core component of universal health coverage; however, geographic accessibility remains highly variable across many low-and middle-income countries (LMICs) [1,2].”
Reuben, W., Nyondo, G. G., Sangeda, R. Z., & Ngoma, S. J. (2026) · SSM - Health Systems · doi:10.1016/j.ssmhs.2026.100183 · Cited by 1
Marin, G. H., Capallo, A. P., Cocco, M. H., Álvarez, J. I., Leone, F. F., Pesci, S. A., Konfino, J., & Kreplak, N. (2026) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2026.21
Gerritse, S. L., van Meerten, E., Duits, A., & Schnog, J. B. (2026) · Cancer Medicine · doi:10.1002/cam4.71817
Mary, F., Alam, M. Z., & Alam, A. S. (2026) · TAJ Journal of Teachers Association · doi:10.70818/taj.v39i2.0646
Haq, M. U. U., Mushtaq, S., Jamshed, S., Quddoos, O., Tareen, A. R., Khan, M. S., Ahmad, Q., Khan, A., & Fang, Y. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14792-9
“…80% in the government sector for both OBs and LPGs, and several medicines reached or exceeded 80% availability in the private sector for either OBs or LPGs (but not for both brand types for the same medicine), a pattern consistent with past WHO/HAI surveys in Pakistan and other LMICs [24, 26, 27].”
Clustering of countries based on national essential medicines lists: cross-sectional study
Buadu, A., Haq, M. Z. U., Heredia, C., Rizvi, A., Workentin, A., & Persaud, N. (2026) · BMJ Global Health · doi:10.1136/bmjgh-2026-024404
Determinants of inequalities in pregnant women’s access to medicines in Cameroon
Nchintouo, Y. N., Nzepang, F., & Anya, S. B. N. (2026) · Journal of Public Health Research · doi:10.1177/22799036261495150 · Cited by 1
Metadata
- Authors
- Bazargani, Y. T., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K.
- Affiliations
- Utrecht University (NL)
- Health Action International (NL)
- Corresponding author
- Mantel-Teeuwisse, Aukje K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-12
- Volume
- 9
- Issue
- 2
- Pages
- e87576
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3922716
- OpenAlex
- W2149749469
- Cited by
- 126
- References
- 31
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 17 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 7 · 2017: 20 · 2016: 5 · 2015: 6 · 2014: 3
- FWCI
- 28.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- essential medicines, drug availability, National List of Essential Medicines, World Health Organization, public sector, private sector, generic drugs, health equity, country income level, WHO regions, therapeutic groups, pharmaceutical access
- MeSH terms
- Health Services Accessibility, Health Services Needs and Demand, Humans, Global Health, World Health Organization, Private Sector, Public Sector, Drugs, Essential, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.